Respiratory Disorders Clinical Trial
Official title:
Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease (COPD) and During Acute Exacerbations of COPD (AECOPD), in Asia Pacific
Since the infectious aetiology of AECOPD has been suggested to vary according to geographical region, the primary purpose of this study (which will be conducted in several countries in Asia Pacific) is to evaluate the occurrence of bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD. Given the increasing and projected burden of COPD in the Asia Pacific region, this study will also evaluate the frequency, severity and duration of AECOPD, as well as the impact of AECOPD on health-related quality of life (HRQOL), healthcare utilisation and lung function.
The protocol has been amended to implement the following changes: - Alignment of the protocol to the updated GOLD consensus report of 2017 and the COPD fact sheet. - Alignment of the study endpoints to the study objectives. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00844935 -
Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients
|
N/A | |
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Completed |
NCT01395849 -
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
|
N/A | |
Completed |
NCT03557645 -
Ventilator Hyperinflation and Hemodynamics
|
N/A | |
Completed |
NCT03281876 -
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
|
Phase 2 | |
Completed |
NCT01395862 -
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
|
N/A | |
Completed |
NCT01476046 -
Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT01587807 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057
|
Phase 1 | |
Completed |
NCT00835003 -
Timing of Planned Caesarean Section and Morbidity of the Newborn
|
N/A | |
Completed |
NCT03443427 -
A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
|
Phase 2 | |
Completed |
NCT01360398 -
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
|
N/A | |
Completed |
NCT03201211 -
A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
|
Phase 1 | |
Completed |
NCT02075541 -
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.
|
Phase 2 | |
Completed |
NCT00455767 -
Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
|
Phase 2 | |
Withdrawn |
NCT01505556 -
Proprioceptive Postural Control and Diaphragm Paresis
|
||
Completed |
NCT01505582 -
Inspiratory Muscle Training and Low Back Pain
|
N/A | |
Completed |
NCT02322671 -
Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01818024 -
A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT02316379 -
Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration
|
Phase 1/Phase 2 | |
Completed |
NCT01516437 -
A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD
|
N/A |